IONS · Ionis Pharmaceuticals, Inc.
$42.93
-2.23% last session
End-of-day data · close of 2026-10-23
Market cap
$7B
Enterprise value
$7B
Trailing P/E
—
Forward P/E
-37.5
Dividend yield
0.0%
Beta
0.38
Avg volume
3M
Employees
1K
Daily Change %
-2.23%
5 Days Change
2.26%
10 Days Change
3.61%
30 Days Change
-0.05%
60 Days Change
-29.22%
Month to Day Change
-0.20%
Year to Day Change
-44.50%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IONS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-22
Latest call per bank · past 12 months
UBS
Buy$88.00
+105.0% vs priceJP Morgan
Overweight$70.00
+63.1% vs priceBarclays
Overweight$85.00
+98.0% vs priceMorgan Stanley
Overweight$104
+142.3% vs priceGoldman Sachs
Neutral$56.00
+30.4% vs priceWells Fargo
Overweight$95.00
+121.3% vs priceRBC Capital
Outperform$85.00
+98.0% vs priceCitigroup
Buy$100
+132.9% vs priceJefferies
Buy$90.00
+109.6% vs priceBank of America
Buy$111
+158.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | BMO Capital | Upgrade | Market Perform → Outperform | $54.00 → $66.00 |
| 2026-10-15 | UBS | Upgrade | Neutral → Buy | $46.00 → $88.00 |
| 2026-09-24 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 2026-09-22 | JP Morgan | Maintains | Overweight | $76.00 → $70.00 |
| 2026-09-15 | Guggenheim | Maintains | Buy | $89.00 → $80.00 |
| 2026-09-09 | Barclays | Maintains | Overweight | $90.00 → $85.00 |
| 2026-09-08 | Morgan Stanley | Maintains | Overweight | $110 → $104 |
| 2026-09-08 | Goldman Sachs | Maintains | Neutral | $69.00 → $56.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 15.0% below the 50-day MA ($50.52).
- bearish: Price vs 200-day MA: Trading 36.6% below the 200-day MA ($67.69).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.47) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($42.38).
IONS Price Chart
Loading chart for IONS…
Fundamentals
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.